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Abstract
Background: Granulocyte Colony-Stimulating Factor (G-CSF) has remarkable neuroprotective properties. Due to its 
proven safety profile, G-CSF is currently used in clinical stroke trials. As neuroprotectants are considered to be more 
effective in the early phase of cerebral ischemia and during reperfusion, G-CSF should to be tested in combination with 
thrombolysis. Therefore, combination therapy was investigated in an experimental model of thromboembolic stroke.
Methods: Male Wistar rats (n = 72) were subjected to a model of thromboembolic occlusion (TE) of the middle 
cerebral artery. Different groups (n = 12 each) treated by recombinant tissue-plasminogen activator (rt-PA) or/and G-
CSF: group control (control), group early G-CSF (G-CSF 60 min after TE), group rt-PA (rt-PA 60 min after TE), group com 
(combination rt-PA/G-CSF), group delayed rt-PA (rt-PA after 180 min), group deco (G-CSF after 60 min, rt-PA after 180 
min). Animals were investigated by magnetic resonance imaging (MRI) and silver infarct staining (SIS) 24 hours after TE.
Results: Early G-CSF or rt-PA reduced the infarct size compared to all groups (p < 0.05 to p < 0.01) with the exception of 
group com, (p = n.s.) as measured by T2, DWI, and SIS. Late administration of rt-PA lead to high mortality and larger 
infarcts compared to all other groups (p < 0.05 to p < 0.01). Pre-treatment by G-CSF (deco) reduced infarct site 
compared to delayed rt-PA treatment (p < 0.05). G-CSF did not significantly influence PWI when combined with rt-PA. 
All animals treated by rt-PA showed improved parameters in PWI indicating reperfusion.
Conclusions: G-CSF was neuroprotective when given early after TE. Early combination with rt-PA showed no 
additional benefit compared to rt-PA or G-CSF alone, but did not lead to side effects. Pretreatment by G-CSF was able 
to reduce deleterious effects of late rt-PA treatment.
Granulocyte Colony-Stimulating Factor (G-CSF) is neu-
roprotective in models of acute experimental cerebral
ischemia [1-9]. During the acute phase of ischemic
stroke, various neuroprotective effects of G-CSF have
been described in different species [1,2,9]. G-CSF influ-
ences apoptotic pathways [3,4], suppresses edema forma-
tion and interleukin-1 beta expression [1,6] induces the
cerebral G-CSF receptor [7], and diminishes glutamate
induced neurotoxicity [1,10]. Moreover, reduction of
infarct size is associated with an improved functional
score [6,8,11]. Remarkably, G-CSF reduced the infarct
size even when given 72 hours after induction of cerebral
ischemia [8]. In addition, G-CSF stimulates endogenous
neurogenesis and vascularisation [6,7,9,11,12]. As a
result, clinical studies are currently conducted to test the
safety and effectiveness of G-CSF after acute ischemic
stroke [9,11,13].
Because of its multiple ways of action and good clinical
tolerability for other medical conditions [9], G-CSF might
be an ideal drug for the treatment of acute ischemic
stroke. So far, thrombolysis by recombinant tissue-plas-
minogen activator (rt-PA) within the first 4.5 hours after
symptom onset is the only proven effective therapy for
thromboembolic stroke [14,15]. As recanalisation and
neuroprotection are probably the most promising thera-
peutical approaches in stroke, combination of rt-PA and
G-CSF need to be tested experimentally before using it in
patient trials. G-CSF might decrease infarct volume when
combined with rt-PA, but may interfere with potentially
beneficial effects of rt-PA such as improvement of cere-
bral blood flow (CBF). Additionally, pretreatment by G-
CSF might influence infarct volume and overall outcome
after delayed and therefore potentially harmful reperfu-
sion. In this context, the interaction of rt-PA associated
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pathways and simultaneous treatment by hematopoetic
growth factors is of high clinical relevance, since combi-
nation treatment by erythropoetin (EPO) and rt-PA lead
to increased side effects in a recently published random-
i z e d  s t u d y  [ 1 6 ] .  I t  i s  v e r y  r e m a r k a b l e  t h a t  n o  a n i m a l
experiments have been published for combination of rt-
PA and EPO before starting the clinical study. Therefore,
we investigated whether G-CSF was neuroprotective in a
model of thromboembolic stroke. Moreover, the combi-
nation therapy with rt-PA was evaluated to eludicate
whether G-CSF alters infarct growth in combination
therapy. Pretreatment with G-CSF before delayed rt-PA
administration was investigated to evaluate whether rep-
erfusion associated injury could be influenced.
Materials and methods
Animals and experimental groups
The animal experiments were performed after approval
of the animal care committee (Regierungspräsidium
Karlsruhe, Germany). Before surgery male Wistar rats (n
= 72) weighing 280 to 320 g (Charles-River Deutschland,
Sulzfeld, Germany) were assigned to one of the following
groups.
•  Group control (n = 12): Thromboembolic cerebral
ischemia (TE). No specific treatment.
• Group early G-CSF(n = 12): TE followed by intrave-
nous G-CSF treatment after 60 min.
• Group early rt-PA(n = 12): TE followed by intrave-
nous rt-PA treatment 60 min after TE.
• Group com(n = 12): TE followed by intravenous rt-PA
treatment 60 min after TE and intravenous G-CSF treat-
ment 60 min after TE.
• Group delayed rt-PA(n = 12): TE followed by intrave-
nous rt-PA treatment 180 min after TE.
• Group deco(n = 12): TE followed by intravenous G-
CSF treatment after 60 min and intravenous rt-PA treat-
ment 180 min after TE.
All animals were subjected to MRI monitoring includ-
ing perfusion weighted imaging (PWI), diffusion
weighted imaging (DWI), T2, and T2* at 0.5, 2.5, 4, and
24 hours after TE followed by silver-infarct staining (SIS)
as described below.
Animal preparation
For induction of anesthesia, the animals inhaled a gas
mixture of halothane (Forene; Abott, Wiesbaden, Ger-
many), nitrous oxyide (70%) and oxygen (30%) via a
precalibrated vaporizer (Fortec; Cyprane Keighley,
United Kingdom). The right femoral artery and vein were
cannulated using polyethylene catheters (PE-50; Labok-
ron, Sinsheim, Germany). Body temperature was kept
constant at 37°C with a temperature-controlled heating
pad (Föhr Medical Instruments, Germany) during sur-
gery. The correlation between body temperature, pericra-
nial and intracranial temperature has been shown before
[17].
TE was induced as previously described [18]. Briefly,
the right common carotid (CCA), internal carotid (ICA),
and external carotid artery (ECA) were exposed and fur-
ther dissection identified the origin of the pterygopala-
tine artery (PPA). The ECA and the PPA were
permanently ligated while the CCA was only temporarily
clipped for embolization. A PE 50 catheter was inserted
into the ECA proximal to its ligation and 12 red blood
clots (each 0.35 mm in diameter and 3 mm in length)
were injected at the origin of the right middle cerebral
artery (MCA). The whole surgical procedure lasted 30 to
40 min.
Rt-PA and G-CSF treatment
Rt-PA (Alteplase, Boehringer Ingelheim, Ingelheim am
Rhein, Germany) was infused intravenously at a dose of
10 mg/kg body weight (b.w.). Ten percent were given as a
bolus at the beginning of thrombolysis followed by con-
tinuous infusion over a 30-minute period with a Harvard
pump (Harvard Apparatus). The dose was in accordance
with experimental studies [18,19]. Rt-PA dissolved with 1
ml of saline 0.9%, while pure saline was administered to
the animals in the control group a. Recombinant G-CSF
(Neupogen, Amgen, Thousand Oaks) in a dose of 60 μg/
kg body weight was dissolved in 1 ml of 0.9% saline and
administered over a period of 30 min 60 min after TE.
The dose was in accordance with a previous study [1].
MRI protocol
The animals were examined in a 2.35-T scanner (Biospec
24/40, BRUKER Medizintechnik, Ettlingen, Germany).
An actively shielded gradient coil with an inner diameter
of 120 cm was used. This coil was driven by the standard
150 V/100A gradient power supply. In this configuration,
180 mT/m could be reached in 180 ms. A home-built
birdcage resonator with an inner diameter of 40 mm as
RF coil was used. MRI examination started within 30 min
after TE and was repeated at 2.5 h, 4 h, and 24 h. The pro-
tocol included T2-WI, DWI, T2*, and PWI as described
previously [18,20,21]. For PWI, a bolus of 0.5 mmol/kg
bw gadodiamide (Omniscan®, Amersham, Braunschweig,
Germany) was injected at the scan at 30 min, 2.5 hours,
and 4 hours.
An investigator blinded for the treatment groups mea-
sured the lesion volumes in T2-weighted and DWI-
weighted MR images by tracing the area of hyperintense
regions. The infarct volume was calculated similar to the
method described for SIS staining. The apparent rrCBV
was calculated from the PWI data, as previously
described [18,20,21]. PWI data was assessed in a region
of interest (ROI) with an area of 3 × 3 pixels at the level of
the lateral basal ganglia, which represents a typical isch-Kollmar et al. Experimental & Translational Stroke Medicine 2010, 2:9
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e m i c  r e g i o n  a f t e r  o c c l u s i o n  o f  t h e  M C A.  V a l u e s  w e r e
then calculated in percent of the healthy contralateral
hemisphere.
Measurement of infarct volume by the silver infarct 
staining (SIS) method
The SIS method was used to measure infarct size [18,22].
Following the last MRI investigation after 24 hours, the
animals were scarified and brain slices were stained
according to the SIS method. A modified version of the
semi automated method [23] was used to measure the
cerebral infarct volume and calculated as follows:
Functional neurological outcome
All surviving animal were tested for neurological out-
come using the neuroscore according to Menzies [24]: 0 =
no apparent deficit, 1 = contralateral forelimb flexion; 2 =
decreased grip of contralateral forelimb grip while tail
pulled; 3 = spontaneous movement in all directions, con-
tralateral circling only if pulled by tail; 4 = spontaneous
contralateral circling. The testing was performed by a co-
worker who was blinded for the earlier treatment regi-
men.
Statistical analysis
Values of the result section and figures are presented as
mean ± S.D. However, functional outcome is given as
median and range. After acquiring all the data, the ran-
domization code was broken. ANOVA and subsequent
post hoc Fisher protected least significant difference tests
were used. A value of p < 0.05 was considered statistically
significant. Animals that died before the endpoint of 24
hours were not excluded from MRI, but SIS analysis. The
nonparametric Kruskall-Wallis test evaluated the neuro-
score with subsequent group comparisons by Mann-
Whitney U test. The Chi square test with Yates correc-
tion for small numbers was used to test for differences
mortality rate.
Results
Physiological variables
There were no significant differences in the physiologic
variables (data not shown).
Survival
Survival rate was 75% for the control group, the early G-
CSF group, the early rt-PA group, and the deco group.
83% of the animals survived in com group. In contrast,
most animals died in the delayed rt-PA group which was
treated by rt-PA 180 min after TE. Only 5 animals sur-
vived 24 hours in this subgroup which corresponds to a
survival rate of 41%. Therefore, the survival rate was sig-
nificantly lower compared to all other experimental
groups (p < 0.05). Animals that died prematurely were
assessed for the cause of death and showed all large
infarcts in the brain territory supplied by the MCA.
Therefore, large infarct was probably responsible for the
death.
Functional outcome
Functional outcome was as follows: control group
showed a median of 2 (range 2-3), the early G-CSF group
had a median of 2 (range 1-2) and the early G-CSF group
a median of 2 (range 1-2). Animals of the early combina-
tion group showed a non significant trend towards a bet-
ter outcome compared to all other groups, since the
median Menzies score was 1 (range 1-2). Animals of the
group which received delayed rt-PA treatment had a
median score of 3 (range 2-3). Pretreatment with G-CSF
lead to a median Menzies score of 2 (1-3).
Infarct size calculated from SIS after 24 hours
The extent of cerebral infarction was 38 ± 4% of the right,
ischemic hemisphere in the remaining animals of the
delayed rt-PA group, 22 ± 3% in the control group, 17 ±
3% in the early G-CSF group, 14 ± 3% in com group, and
11 ± 3% in the early thrombolysis group. Therefore, the
infarct size in the delayed rt-PA group was larger com-
pared to all others (p < 0.05). Moreover, the infarct size in
the control group exceeded the early G-CSF, early rt-PA
group, and com group (p < 0.05). Animals of the deco
group had larger infarcts compared to early rt-PA, (p <
0.05). There was no difference between the control group
and the deco group (Figure 1 and 2).
Perfusion weighted imaging
Analysis of the relative regional cerebral blood volume
(rrCBV) at the level of the basal ganglia showed a
decrease to below 50% of the corresponding nonischemic
ROIs 30 min after thromboembolic occlusion (data not
Corrected infarct volume volume of the left, non-ischemic  = h hemisphere volume of the right, ishemic hemisphere - inf − (a arct volume).
Figure 1 Infarct volume in SIS. Cerebral infarct is shown as calculated 
from SIS after 24 hours. Infarct size is larger in the control group (con-
trol) compared to early G-CSF (G-CSF), early rt-PA (rt-PA), and early 
combination (com) as indicated by the asterisks (p < 0.05).
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shown). This effect was not different between the groups
(p = ns). The rrCBV slightly was significantly larger in the
rt-PA group and com group compared to all other groups,
(p < 0.001). There were no significant differences in the
groups not treated by rt-PA (p = ns). 4 hours after stroke
onset, rrCBV was larger in the rt-PA group, delayed rt-PA
group and the com group compared to the control group
and the early G-CSF group, (p < 0.005). There was a sig-
nificant difference between the rt-PA group (94 ± 11%),
delayed rt-PA group (91 ± 7%) compared to the deco
group (75 ± 4%; p < 0.05). Data is shown in Table 1.
Diffusion weighted imaging
There were no significant differences between the lesion
size after 0.5 hours as calculated from DWI (p = ns; data
not shown).
DWI lesions after 2.5 hours accounted to 43 ± 5 mm3 in
the control group and were significantly larger than those
observed for the rt-PA group by 26 ± 7 mm3, and early
com group by 21 ± 8 mm3 (p < 0.05), (Data shown in Fig-
ure 3). There was no significant difference compared to
the early G-CSF group by 31 ± 5 mm3, the deco group by
33 ± 5 mm3, and the delayed rt-PA group with 42.7 ± 4
mm3. Animals treated with early G-CSF tended towards
smaller lesions, since the lesion volume was 26 ± 6 mm3
in the early G-CSF group and 21 ± 8 mm3 in the com
group. Early thormbolysis lead to a lesion volume of 25.9
± 9 mm3 (p < 0.05). 4 hours after stroke onset, lesion vol-
ume was larger in the delayed rt-PA group (135.8 ± 22
mm3) than in the deco group (80.2 ± 14 mm3; p < 0.05),
the early G-CSF group (65.1 ± 17 mm3; p < 0.005), and
early rt-PA (57 ± 17 mm3; p < 0.005). After 24 hours, the
lesion volume of the delayed rt-PA group was 180 ± 13
mm3 and significantly larger than in the control group
(102.4 ± 11 mm3; p > 0.001), the early G-CSF group (71.1
± 8 mm3; p < 0.001), the deco group (87.3 ± 12 mm3; p >
0.001), and the early rt-PA group (68.3 ± 9 mm3; p >
0.001). Moreover, lesion volume in the early G-CSF group
and the early rt-PA group was smaller than in the control
group (p < 0.05).
Values of DWI after 24 hours show significant differ-
ences between the treatment groups (Table 1 and 2). The
infarct volume was larger in the control group a vs. early
G-CSF group (p = 0.019), to early rt-PA group (p = 0.006),
and the com group (p = 0.013). No treatment resulted in
smaller infarct volume than G-CSF plus delayed rt-PA
administration in group deco (p = 0.002). There was a
non-significant trend towards smaller infarct volume in
group deco compared to the control group (p = 0.25; n.s.).
Comparing the early treatment group G-CSF and rt-PA,
there was no difference for the infarct volume. Combin-
ing rt-Pa and G-CSF (group com) in the early phase lead
to smaller infarct than for rt-PA treatment alone (p =
0.001). Early rt-PA treatment (group rt-PA) and combina-
tion (group com) lead to smaller infarcts than in group
delayed rt-PA (p = 0.001). Pretreatment by G-CSF in
combination with delayed rt-PA in group deco reduced
the infarct volume compared to the delayed rt-PA group
(p = 0.001).
T2-WI and T2*-WI
There were no significant differences among all groups at
the first scan after 30 min (data not shown) and after 2.5
hours (p = ns). After 4 hours, lesion size in the delayed rt-
PA group was 129.4 ± 14.4 mm3 and therefore larger than
in the early G-CSF group (65.3 ± 18 mm3), the com group
(68.1 ± 13 mm3), and the rt-PA group (58.1 ± 12 mm3); (p
< 0.005). After 24 hours, infarct size was larger in the con-
trol (113 ± 7 mm3) compared to the early G-CSF group
(85.5 ± 8 mm3; p < 0.05), the com group (70.3 ± 15 mm3; p
< 0.01), and the early rt-PA group (59.1 ± 8 mm3); (p <
0.005). However, infarct size in the control group was
smaller compared to the delayed rt-AP group (193.3 ± 5
mm3; p < 0.001). Moreover, the lesion size in the delayed
rt-PA group was larger than in the com group, the early
G-CSF group, and early rt-PA group (p < 0.001). T2*-WI
showed 4 animals (one in each group excluding early
thrombolysis) with an intra-cerebral hemorrhage.
4. Discussion
This study shows for the first time that G-CSF reduces
infarct volume in a model of thromboembolic stroke.
Moreover, it prevents some deleterious effects of delayed
rt-PA treatment in terms of infarct growth and mortality
during an observation time of 24 hours after stroke onset.
These results are an important step towards further clini-
cal investigations on G-CSF and acute stroke, since the
EPO trial failed because of deleterious combination ther-
apy of EPO and rt-PA [16].
Figure 2 Infarct volume in SIS after delayed rt-PA treatment. Cere-
bral infarct is shown as calculated from SIS after 24 hours. Infarct size is 
larger in the delayed rt-PA group (delayed rt-PA) compared to the con-
trol group (control), and delayed combination (deco) as indicated by 
the asterisks (p < 0.05).
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Table 1: Data of serial MRI.
DWI in mm3
2.5 hrs 4 hrs 24 hrs
control 43 ± 5 86 ± 14 102 ± 11
early G-CSF 31 ± 5 65 ± 17 71 ± 8
rt-PA 26 ± 7 57 ± 17 68 ± 9
com 21 ± 8 49 ± 14 65 ± 11
delayed rt-PA 43 ± 4 136 ± 22 180 ± 13
deco 33 ± 5 80 ± 14 87 ± 12
T2 in mm3
4 hrs 24 hrs
control 79 ± 12 113 ± 7
early G-CSF 65 ± 18 85 ± 8
rt-PA 68 ± 13 69 ± 8
com 54 ± 16 70 ± 15
delayed rt-PA 129 ± 14 193 ± 15
deco 68 ± 13 93 ± 13
PWI in %
2.5 hrs 4 hrs
control 28 ± 3 58 ± 7
early G-CSF 34 ± 5 53 ± 8
rt-PA 78 ± 4 94 ± 11
com 75 ± 6 91 ± 7Kollmar et al. Experimental & Translational Stroke Medicine 2010, 2:9
http://www.etsmjournal.com/content/2/1/9
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Neuroprotective effects of G-CSF
Recent experimental studies showed that G-CSF is bene-
ficial after cerebral ischemia and brain injury [1-8]. While
neuroprotective effects are described in the early stage of
brain injury, G-CSF also stimulates neuronal progenitor
cells providing a link to functional recovery [6,9]. G-CSF
reduces infarct volume after transient suture occlusion of
the MCA and protects neurons against glutamate-
induced excitotoxicity in cell culture [1,10]. Further neu-
roprotective mechanisms include an increased STAT3
regulation in the penumbra of G-CSF-treated rats. Effects
of G-CSF are probably mediated by a special neuronal G-
CSF receptor [1,7], since G-CSF passes even the intact
the blood-brain-barrier [7] and therefore reaches injured
brain regions. Moreover, G-CSF seems to have additional
regenerative effects as bone marrow cells are activated.
Neuronal plasticity and vascularisation were proven in
experimental studies of cerebral ischemia [6,7].
G-CSF compared to early thrombolysis
So far, G-CSF was not tested in models of thromboembo-
lic stroke. However, this step is essential when transfer-
ring neuroprotective agents to stroke patients. If
neuroprotectants are successful at all, the chance is the
highest in early stages of stroke. In this study, MRI-data
as well as SIS showed that G-CSF was as effective as early
thrombolysis in terms of reduction of infarct volume.
There was no difference in mortality as well. G-CSF did
not influence rrCBV compared to the control group. As
expected, early rt-PA treatment resulted in almost com-
plete normalisation of rrCBV. It can be suggested that the
mentioned multiple neuroprotective effects contribute to
reduction of infarct for this subgroup. These results are in
accordance to former studies in suture occlusion model
[1,6].
G-CSF prior to delayed thrombolysis
G-CSF reduced infarct volume and mortality when given
prior to delayed rt-PA treatment. Moreover, there was no
significant difference to early rt-PA and G-CSF treatment
alone. In accordance to data of the suture occlusion
model, delayed restoration of CBF leads to larger infarct
than early restoration. Aronowski et al. observed larger
infarct volumes and edema as compared to permanent
ischemia, when the MCA occluding suture was removed
120 to 300 min after induction of ischemia [25]. Clinical
data shows that delayed thrombolysis beyond the three
hours window in already demarked infarct increases the
risk of side effects such as hemorrhage or enlargement of
infarction [14]. Probably these side effects are caused by
reperfusion-associated injury and neurotoxic properties
of rt-PA [26,27]. In contrast to the patient, infarct mature
much faster in rats and therefore a time window of three
hours can be considered as late thrombolysis. In accor-
dance, early rt-PA treatment lead to smaller infarcts com-
pared to the control group, while delayed administration
of rt-PA increased infarct volume and mortality in this
study. It can be suggested that G-CSF helps to prolong the
time window for thrombolysis. This is of importance,
since the transport of patients to the clinic is often long
and excludes them from thrombolytic treatment. Pre-
treatment In the ambulance car or if the treatment with
rt-PA is delayed in the hospital might be helpful for these
subgroup of stroke patients.
However, there are several limitations of the study. Cer-
tainly, observation periods of more than 24 hours are
necessary to test whether effects of neuroprotectants are
transient or permanent. Moreover, further investigations
should address whether G-CSF interacts with rt-PA and
delayed rt-PA 34 ± 3 90 ± 5
deco 38 ± 7 75 ± 4
These are given as means ± SD for different time points after stroke onset.
Table 1: Data of serial MRI. (Continued)
Figure 3 Lesion volume in MRI. Lesion volume is shown as calculat-
ed from DWI and expressed as means ± SD. The lesion volume in the 
control group was larger compared to early rt-PA (rt-PA) and early com-
bination group (com) after 2.5 hours, and larger than the early rt-PA, 
early G-CSF (G-CSF) and early combination group after 4 and 24 hours 
as shown by the single asterisks. Delayed rt-PA treatment (delayed rt-
PA) resulted in larger lesion volume than the early rt-PA, early G-CSF 
and early combination group after 2.5 hours, and additionally larger 
than the control group after 4 hours. It was larger than all others after 
24 hours as shown by the string sign. The late combination group 
(deco) showed larger infarcts than the early combination after 2.5 
hours. After 4 hours, lesion volume was larger than all others with ex-
ception of delayed rt-PA. After 24 hours, there was a difference com-
pared to the early rt-PA and early combination as indicated by the 
double asterisks. Levels of significance are given in table 2.
c
o
n
t
r
o
l
c
o
n
t
r
o
l
c
o
n
t
r
o
l
e
a
r
l
y
 
G
-
C
S
F
e
a
r
l
y
 
G
-
C
S
F
e
a
r
l
y
 
G
-
C
S
F
r
t
-
P
A
r
t
-
P
A
r
t
-
P
A
c
o
m
c
o
m
c
o
m
d
e
l
a
y
e
d
 
r
t
-
P
A
d
e
l
a
y
e
d
 
r
t
-
P
A
d
e
l
a
y
e
d
 
r
t
-
P
A
d
e
c
o
d
e
c
o
d
e
c
o
 
0
50
100
150
200
2.5hrs 4hrs 24hrs
hours after thromboembolic stroke
l
e
s
i
o
n
 
v
o
l
u
m
e
 
i
n
 
m
m
³
*
*
*
$
$
** **
**
$Kollmar et al. Experimental & Translational Stroke Medicine 2010, 2:9
http://www.etsmjournal.com/content/2/1/9
Page 7 of 9
Table 2: Comparing diffusion-weighted imaging
after 2.5 
hours
control early
G-CSF
rt-PA com delayed rt-PA deco
control n.s. < 0.05 < 0.05 n.s. n.s.
early G-CSF n.s. n.s. n.s. < 0.05 n.s.
rt-PA < 0.05 n.s. n.s. < 0.05 n.s.
com n.s. n.s. n.s. < 0.05 n.s.
delayed rt-PA n.s. < 0.05 < 0.05 < 0.05 n.s.
deco n.s. n.s. n.s. < 0.05 n.s.
after 4 hours
control early
G-CSF
rt-PA com delayed rt-PA deco
control n.s. p < 0.05 p < 0.01 < 0.05 n.s.
early G-CSF n.s. n.s. n.s. < 0.005 n.s.
rt-PA p < 0.05 n.s. n.s. < 0.005 n.s.
com p < 0.01 n.s. n.s. < 0.005 n.s.
delayed rt-PA < 0.05 < 0.005 < 0.005 < 0.005 < 0.05
deco n.s. n.s. n.s. n.s. < 0.05
after 24 
hours
control early
G-CSF
rt-PA com delayed rt-PA deco
control < 0.05 < 0.05 < 0.05 < 0.001 n.s.
early G-CSF < 0.05 n.s. n.s. < 0.001 n.s.Kollmar et al. Experimental & Translational Stroke Medicine 2010, 2:9
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CBF. Autoradiographic techniques may answer these
questions, but were not in the focus of the present study.
Animals were exposed to anesthesia for several hours.
While this could interfere with mortality overall, differ-
ences between the groups cannot explained with it.
Although we did not investigate further pathways of G-
CSF and combination with rt-PA, this study is essential
when G-CSF will be investigated in patients treated by rt-
PA.
In conclusion, the results of the present study are
encouraging on the path of new therapies for ischemic
stroke. G-CSF represents an interesting and promising
candidate for stroke therapy because of its neuroprotec-
tive properties, potential induction of stem cells and good
clinical tolerance in hematological patients. Further
experimental studies have to investigate combination
therapy of G-CSF and rt-PA over longer time periods,
since combining the so far best medical therapy rt-PA
with new drugs represents a logical and potentially suc-
cessful way for stroke treatment.
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